Miltefosine

(Impavido®)

Impavido®

Drug updated on 11/9/2023

Dosage FormCapsule (oral: 50 mg)
Drug ClassAntileishmanials
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For treatment of visceral leishmaniasis due to Leishmania donovani in adults and adolescents ≥12 years of age weighing ≥30 kg.
  • For treatment of cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis in adults and adolescents ≥12 years of age weighing ≥30 kg.
  • For treatment of mucosal leishmaniasis due to Leishmania braziliensi in adults and adolescents ≥12 years of age weighing ≥30 kg.